News

Amylin deal: AZ steps in
Enlarge image

BusinessUKSweden

Amylin deal: AZ steps in

10.08.2012 - AstraZeneca made an initial payment of approximately US$3.2bn to include Amylin’s portfolio of diabetes candidates into the joint diabetes alliance.

Bristol-Myers Squibb (BMS) has completed its acquisition of Amylin Pharmaceuticals worth US$5.3bn in cash. After getting hold of 85% of common stock of the company for US$31 per share, BMS has exercised its right to snap up the remaining stock and finalise the merger. The company plans to delist and de-register Amylin common stock as promptly as practicable following the effective time of the merger.

This triggered an initial payment of approximately US$3.2bn by the British-Swedish pharma company AstraZeneca, which already has a major diabetes partnership with BMS. AstraZeneca previously agreed to pay US$3.4bn for 50% of the profits from Amylin’s drugs. Additionally, AstraZeneca has opted to pay a further US$135m to get an equal say in certain key strategic and financial decisions regarding Amylin’s portfolio. This decision had been widely expected. It will become only effective, if applicable anti-trust and competition approvals are received by AstraZeneca.

Amylin's products for the fast-growing type 2 diabetes market included among others Byetta (exenatide) and the longer-acting version Bydureon. The original alliance had been focused on the development of the DPP-4 inhibitor Onglyza (saxagliptin), Kombliglyze (saxagliptin and metformin HCL extended-release), and the SGLT2 inhibitor Forxiga (idapagliflozin).

http://www.european-biotechnology-news.com/news/news/2012-03/amylin-deal-az-steps-in.html

Personalised MedicineNetherlandsBelgiumSpain

02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

BiofuelFinlandSwedenUK

10.06.2015 St1 Biofuels has expanded beyond the Finnish borders and opened a bioethanol plant in Sweden. The plant will convert leftovers and waste from bakeries to biofuel.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BAVARIAN NORDIC (D)44.62 EUR12.34%
  • MOLOGEN (D)5.20 EUR7.00%
  • BRITISH TECHNOLOGY GROUP (UK)686.00 GBP6.94%

FLOP

  • CYTOS (CH)0.50 CHF-9.09%
  • NOVACYT (F)4.99 EUR-6.90%
  • EPIGENOMICS (D)5.12 EUR-5.19%

TOP

  • DBV Technologies (F)54.26 EUR26.8%
  • VERONA PHARMA (UK)5.10 GBP17.2%
  • MEDIGENE (D)9.72 EUR16.0%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • TRANSGENE (F)3.80 EUR-26.9%
  • NORDIC NANOVECTOR (N)25.50 NOK-25.9%

TOP

  • ADOCIA (F)66.29 EUR388.1%
  • 4SC (D)4.90 EUR375.7%
  • VERONA PHARMA (UK)5.10 GBP314.6%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • ACTIVE BIOTECH (S)9.00 SEK-70.1%
  • NEOVACS (F)1.14 EUR-69.1%

No liability assumed, Date: 02.07.2015